29th Mar 2005 07:00
Oxford Biomedica PLC29 March 2005 FOR IMMEDIATE RELEASE 29 MARCH 2005 OXFORD BIOMEDICA: NOTIFICATION OF ANNUAL GENERAL MEETING Oxford, UK: 29 March 2005 - Oxford BioMedica (LSE: OXB), the leading genetherapy company, announces today that it will be holding its Annual GeneralMeeting on 10 May 2005, 11.00am, at the offices of Morrison & Foerster MNP,CityPoint, One Ropemaker Street, London EC2Y 9AW. A notice of AGM will be sentto shareholders on 5 April 2005. -Ends- For further information, please contact:Oxford BioMedica plc:Professor Alan Kingsman, Chief Executive Tel: +44 (0)1865 783 000City/Financial Enquiries:Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan Tel: +44 (0)20 7466 5000CommunicationsScientific/Trade Press EnquiriesSue Charles/ Katja Stout/ Ashley Lilly Tel: +44 (0)20 7886 8150Northbank Communications Notes to editors: 1. Oxford BioMedicaOxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in thedevelopment of novel gene-based therapeutics with a focus on the areas ofoncology and neurotherapy. The Company was established in 1995 as a spin outfrom Oxford University, and is listed on the London Stock Exchange. Oxford BioMedica has core expertise in gene delivery, as well as in-houseclinical, regulatory and manufacturing know-how. In oncology, the pipelineincludes an immunotherapy and a gene therapy in multiple Phase II trials, and apreclinical targeted antibody therapy in collaboration with Wyeth. Inneurotherapy, the Company's lead product is a gene therapy for Parkinson'sdisease, which is expected to enter clinical trials in early 2006, and fourfurther preclinical candidates. The Company is underpinned by over 80 patentfamilies, which represent one of the broadest patent estates in the field. The Company has a staff of approximately 65 split between its main facilities inOxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California.Oxford BioMedica has corporate collaborations with Wyeth, Intervet, Amersham,Viragen, MolMed and Kiadis; and has licensed technology to a number of companiesincluding Merck & Co and Biogen Idec. Further information is available at www.oxfordbiomedica.co.uk. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Oxford Biomedica